GC Biopharma (006280) Fundamentals 2026 — Revenue Analysis | SniperIQ
GC Biopharma (006280) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩1.35T, trading at ₩118700.00 on the KSC. This SniperIQ fundamentals page covers GC Biopharma's valuation, profitability (net margin -0.7%), revenue (₩1.99T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GC Biopharma's market cap?
GC Biopharma (006280) has a market capitalization of approximately ₩1.35T, trading at ₩118700.00 on the KSC. Market cap moves with the live share price.
What is GC Biopharma's P/E ratio?
GC Biopharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GC Biopharma?
GC Biopharma runs a net profit margin of -0.7%, a gross margin of 26.5%, and an operating margin of 3.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GC Biopharma generate?
GC Biopharma reported revenue of ₩1.99T for fiscal year 2025, with net income of -₩4.7B and earnings per share (EPS) of -409.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GC Biopharma pay a dividend?
GC Biopharma offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is GC Biopharma financially healthy?
GC Biopharma carries a debt-to-equity ratio of 0.74x and a current ratio of 1.25x, with a market beta of 0.75. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GC Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GC Biopharma (006280) the key facts are: market cap ₩1.35T, revenue ₩1.99T, 52-week range 115900-183800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GC Biopharma's full fundamentals live
Get GC Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.